首页> 外文期刊>Cancer biology & therapy >MicroRNA-21 A novel therapeutic target in human cancer
【24h】

MicroRNA-21 A novel therapeutic target in human cancer

机译:MicroRNA-21新型人类癌症治疗靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Resistance to anticancer agents is a major clinical obstacle to the successful treatment of cancer, yet the mechanisms underlying drug resistance have not been fully characterized. MicroRNAs (miRNAs) are endogenous, small (19-25 nucleotides in length) noncoding RNAs, which function by base pairing with messenger RNAs, thereby regulating protein expression. Emerging evidence shows that alteration of miRNAs is involved in cancer initiation and progression. MiR-21 is a miRNA that is overexpressed in most tumor types, and acts as an oncogene by targeting many tumor suppressor genes related to proliferation, apoptosis and invasion. In vivo and in vitro studies suggest that miR-21 may serve as a diagnostic and prognostic marker for human malignancies. More recently, studies have identified an important role for miR-21 in anticancer drug resistance. Here, we review the mechanisms underlying miR-21-mediated chemoresistance and the potential use of miR-21 as a novel molecular target for cancer chemotherapy.
机译:对抗癌药的抗药性是成功治疗癌症的主要临床障碍,但抗药性的潜在机制尚未得到充分表征。微小RNA(miRNA)是内源的,小的(长度为19-25个核苷酸)非编码RNA,其通过与信使RNA碱基配对来发挥功能,从而调节蛋白质表达。新兴证据表明,miRNA的改变与癌症的发生和发展有关。 MiR-21是在大多数肿瘤类型中过表达的miRNA,并且通过靶向许多与增殖,凋亡和侵袭有关的肿瘤抑制基因而作为癌基因。体内和体外研究表明,miR-21可以作为人类恶性肿瘤的诊断和预后标志物。最近,研究确定了miR-21在抗癌药物耐药性中的重要作用。在这里,我们审查了miR-21介导的化学抗性的潜在机制以及miR-21作为癌症化疗的新型分子靶标的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号